Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug–drug interaction (DDI) studies. This work by an International Consortium for Innovation and Quality in Pharmaceutical Development working group (WG) is to develop and verify...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:CPT Pharmacometrics Syst Pharmacol
Main Authors: Chen, Yuan, Cabalu, Tamara D., Callegari, Ernesto, Einolf, Heidi, Liu, Lichuan, Parrott, Neil, Peters, Sheila Annie, Schuck, Edgar, Sharma, Pradeep, Tracey, Helen, Upreti, Vijay V., Zheng, Ming, Zhu, Andy Z.X., Hall, Stephen D.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6765698/
https://ncbi.nlm.nih.gov/pubmed/31215774
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados